## **OPTIMA HEALTH PLAN**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If information provided is not complete</u>, correct, or legible, authorization may be delayed.

**<u>Drug Requested: Topical Acne Drugs</u>** (check applicable box below)

□ PREFERRED: adapalene (Differin®) cream/gel/solution **	□ PREFERRED: tretinoin (Retin®-A) cream 0.025%, 0.05%, 0.1%; gel 0.01%, 0.025%**				
**generic adapalene and tretinoin products require prior authorization if used as treatment in a member greater than 29 years of age					
□ adapalene 0.3%/benzoyl peroxide 2.5% gel (generic for Epiduo Forte®)	□ Altreno® (tretinoin) lotion 0.05%				
□ Aklief® (trifarotene) cream 0.005%	□ Amzeeq® (minocycline) topical foam 4%				
□ Azelex® (azelaic acid) cream 20%	□ clindamycin 1.2%/benzoyl peroxide 2.5% gel (Acanya®)				
□ dapsone gel 5% (Aczone®)	□ Fabior® (tazarotene) foam 0.1%				
□ Retin®-A Micro (tretinoin microsphere) 0.06%, 0.08% gel	□ tazarotene cream 0.1% (Tazorac®)				
□ tretinoin gel 0.05% (Atralin®)	□ tretinoin microsphere gel 0.04%,0.1% (Retin®-A Micro)				
□ Winlevi® (clascoterone) cream 1%					
DRUG INFORMATION: Authorization may be delayed if incomplete.					
Drug Form/Strength:					
Dosing Schedule:	Length of Therapy:				
Diagnosis:	ICD Code, if applicable:				
<b>CLINICAL CRITERIA:</b> Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied					

<sup>\*\*</sup>NOTE: Adapalene and all tretinoin based medications are restricted to **NON-COSMETIC** purposes

<sup>\*\*</sup>generic adapalene and tretinoin products require prior authorization if used as treatment in a member greater than 29 years of age.

For f	orn	nul	ary preferred adapalene or tretinoin product requests:		
			esting a formulary preferred adapalene or tretinoin product, member has <b>ONE</b> of the following		
	diagnoses				
		Di	agnosis (for generic adapalene or tretinoin requests):		
			Acne vulgaris and member is greater than 29 years of age		
			Rosacea and member is greater than 29 years of age		
			Medication is being requested for a diagnosis not listed on prior authorization form and provider has submitted rationale for medical necessity of use with supporting clinical documentation below		
		Di	agnosis (for generic tretinoin requests only):		
			Actinic keratosis and member is greater than 29 years of age		
			Medication is being requested for a diagnosis not listed on prior authorization form and provider has submitted rationale for medical necessity of use with supporting clinical documentation below		
adeqı	ıate	ben	efit.		
		-			
			er topical acne drug requests (excluding formulary preferred adapalene or		
tretin	101I	ı pı	<u>oducts)</u> :		
☐ For all other topical acne		r all	other topical acne drug requests, member must meet <b><u>BOTH</u></b> of the following:		
		Me	ember has been diagnosed with acne vulgaris		
			ember must have documentation of at least a 30 day trial and failure of THREE (3) of the lowing:		
			adapalene 0.1% cream/solution/gel or 0.3% gel (generic Differin®) **		
			adapalene 0.1%/benzoyl peroxide 2.5% gel (generic Epiduo®)		
			benzoyl peroxide OTC		
			benzoyl peroxide 1%, 1.2%/clindamycin 5% gel (generic BenzaClin® & Neuac®/Duac® gel)		
			benzoyl peroxide 5%/erythromycin 3% gel (generic Benzamycin)		
			clindamycin 1% topical		
			erythromycin 2% topical		

(Continued on next page; signature page must be attached to this request form)

□ tretinoin (generic Retin-A®) 0.025%, 0.05%, 0.1% cream or 0.01%, 0.025% gel \*\*

## (Please ensure signature page is attached to form)

## Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*

Member Name:		
	Deta of Divide	
Member Optima #:		
Prescriber Name:		
Prescriber Signature:	Date:	
Office Contact Name:		
Phone Number:	Fax Number:	
DEA OR NPI #: *Approved by Pharmacy and Therapeutics Committee: 4/17/2014		
*Approved by Pharmacy and Therapeutics Committee: 4/17/2014		

REVISED/UPDATED: 5/8/2014; 5/28/2014; 6/10/2014; 7/29/2014; 8/6/2014; 9/23/2014; 11/5/2014; 2/19/2015; 5/27/2015; 7/23/2015; 8/11/2015;

6/15/2022; 6/16/2022; 10/24/2022